Clinical proteomics: From biomarker discovery and cell signaling profiles to individualized personal therapy

Bioscience Reports

Volumn 25, Issue 1-2, 2005, Pages 107-125

  Calvo, Katherine R ^a   Liotta, Lance A ^a   Petricoin, Emanuel F ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Clinical Proteomics; Combinatory theraphy; Mass spectroscopy; Microdissection; Oncology; Pathology; Protein microarrays

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; GEFITINIB; GROWTH FACTOR; IMATINIB; PHOSPHOPROTEIN; PROTEOME; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONFORMATIONAL TRANSITION; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; LASER CAPTURE MICRODISSECTION; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METASTASIS; MICROENVIRONMENT; NANOTECHNOLOGY; NONHUMAN; PROTEIN FUNCTION; PROTEIN MICROARRAY; PROTEIN PROTEIN INTERACTION; PROTEOMICS; SIGNAL DETECTION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

BIOLOGICAL MARKERS; COMBINED MODALITY THERAPY; COMPUTATIONAL BIOLOGY; GENOMICS; HUMANS; MASS SPECTROMETRY; NANOTECHNOLOGY; PROTEIN ARRAY ANALYSIS; PROTEOME; PROTEOMICS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 26444555647     PISSN: 01448463     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10540-005-2851-3     Document Type: Article

References (76)

1. E. S. Lander 2001 Initial sequencing and analysis of the human genome Nature 409 6822 860 921
2. Venter, J. C. et al.
3. J. L. Badano N. Katsanis 2002 Beyond Mendel: an evolving view of human genetic disease transmission Nat. Rev. Genet 3 10 779 789
4. L. M. Staudt 2002 Gene expression profiling of lymphoid malignancies Annu Rev Med 53 303 318
5. M. A. Shipp 2002 Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning Nat. Med 8 1 68 74
6. S. S. Dave 2004 Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells N. Engl. J. Med 351 21 2159 2169
7. D. Singh 2002 Gene expression correlates of clinical prostate cancer behavior Cancer Cell 1 2 203 209
8. T. Sorlie 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets Proc. Natl. Acad. Sci. USA 100 14 8418 8423
9. D. R. Schwartz 2002 Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas Cancer Res 62 16 4722 4729
10. E. F. Petricoin 2002 Clinical proteomics: translating benchside promise into bedside reality Nat. Rev. Drug Discov 1 9 683 695
11. E. F. Petricoin L. A. Liotta 2004 SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer Curr. Opin. Biotechnol 15 1 24 30
12. K. P. Rosenblatt 2004 Serum proteomics in cancer diagnosis and management Annu. Rev. Med 55 97 112
13. A. V. Rapkiewicz 2004 Biomarkers of ovarian tumours Eur. J. Cancer 40 17 2604 2612
14. E. F. Petricoin 2002 Use of proteomic patterns in serum to identify ovarian cancer Lancet 359 9306 572 577
15. Conrads, T. P., et al. (2004) High-resolution serum proteomic features for ovarian cancer detection. Endocrine Related Cancer (in press).
16. J. Li 2002 Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer Clin. Chem 48 8 1296 1304
17. D. K. Ornstein 2004 Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 Ng/Ml J. Urol 172 4, Part 1 of 2 1302 1305
18. E. F. Petricoin 3rd 2002 Serum proteomic patterns for detection of prostate cancer J. Natl. Cancer Inst 94 20 1576 1578
19. E. F. Petricoin D. K. Ornstein L. A. Liotta 2004 Clinical proteomics: applications for prostate cancer biomarker discovery and detection Urol. Oncol 22 4 322 328
20. J. Prados 2004 Mining mass spectra for diagnosis and biomarker discovery of cerebral accidents Proteomics 4 8 2320 2332
21. W. Clarke 2003 Characterization of renal allograft rejection by urinary proteomic analysis Ann. Surg 237 5 660 664 discussion 664-665
22. O. Carrette 2003 A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease Proteomics 3 8 1486 1494
23. E. F. Petricoin 2004 Lessons from Kitty Hawk: from feasibility to routine clinical use for the field of proteomic pattern diagnostics Proteomics 4 8 2357 2360
24. J. D. Wulfkuhle L. A. Liotta E. F. Petricoin 2003 Proteomic applications for the early detection of cancer Nat. Rev. Cancer 3 4 267 275
25. E. F. Petricoin L. A. Liotta 2004 Proteomic approaches in cancer risk and response assessment Trends Mol. Med 10 2 59 64
26. L. A. Liotta E. C. Kohn 2001 The microenvironment of the tumour-host interface Nature 411 6835 375 379
27. L. A. Liotta M. Ferrari E. Petricoin 2003 Clinical proteomics: written in blood Nature 425 6961 905
28. A. I. Mehta 2003 Biomarker amplification by serum carrier protein binding Disease Markers 19 1 1 10
29. D. H. Geho 2004 Opportunities for nanotechnology-based innovation in tissue proteomics Biomed. Microdevices 6 3 231 239
30. J. M. Nam C. S. Thaxton C. A. Mirkin 2003 Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins Science 301 1884 1886
31. K. R. Calvo 2004 Molecular profiling provides evidence of primary mediastinal large B-cell lymphoma as a distinct entity related to classic Hodgkin lymphoma: implications for mediastinal gray zone lymphomas as an intermediate form of B-cell lymphoma Adv. Anat. Pathol 11 5 227 238
32. E. F. Petricoin L. A. Liotta 2003 Clinical applications of proteomics J. Nutr 133 7 Suppl 2476S 2484S
33. L. A. Liotta E. C. Kohn E. F. Petricoin 2001 Clinical proteomics: personalized molecular medicine JAMA 286 18 2211 2214
34. S. H. Moolgavkar A. G. Knudson Jr. 1981 Mutation and cancer: a model for human carcinogenesis J. Natl. Cancer Inst 66 6 1037 1052
35. D. Hanahan R. A. Weinberg 2000 The hallmarks of cancer Cell 100 1 57 70
36. M. R. Emmert-Buck 1996 Laser capture microdissection Science 274 5289 998 1001
37. A. P. Fuller 2003 Laser capture microdissection and advanced molecular analysis of human breast cancer J. Mammary Gland Biol. Neoplasia 8 3 335 345
38. X. J. Ma 2003 Gene expression profiles of human breast cancer progression Proc. Natl. Acad. Sci. USA 100 10 5974 5979
39. C. P. Paweletz L. A. Liotta E. F. Petricoin 3rd 2001 New technologies for biomarker analysis of prostate cancer progression: laser capture microdissection and tissue proteomics Urology 57 4 Suppl 1 160 163
40. D. H. Geho E. F. Petricoin L. A. Liotta 2004 Blasting into the microworld of tissue proteomics: a new window on cancer Clin. Cancer Res 10 3 825 827
41. C. P. Paweletz 2000 Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip Drug Develop. Res 49 34 42
42. K. Yanagisawa 2003 Proteomic patterns of tumour subsets in non-small-cell lung cancer Lancet 362 9382 433 439
43. K. Yanagisawa 2003 Molecular fingerprinting in human lung cancer Clin. Lung Cancer 5 2 113 118
44. S. A. Schwartz 2004 Protein profiling in brain tumors using mass spectrometry: feasibility of a new technique for the analysis of protein expression Clin. Cancer Res 10 3 981 987
45. V. Espina 2003 Protein microarrays: molecular profiling technologies for clinical specimens Proteomics 3 11 2091 2100
46. L. A. Liotta 2003 Protein microarrays: meeting analytical challenges for clinical applications Cancer Cell 3 4 317 325
47. C. P. Paweletz 2001 Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front Oncogene 20 16 1981 1989
48. P. C. Herrmann 2003 Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer Proteomics 3 9 1801 1810
49. R. L. Grubb 2003 Signal pathway profiling of prostate cancer using reverse phase protein arrays Proteomics 3 11 2142 2146
50. J. D. Wulfkuhle 2003 Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays Proteomics 3 11 2085 2090
51. S. Nishizuka 2003 Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays Proc. Natl. Acad. Sci. USA 100 24 14229 14234
52. Petricoin, E. F., et al. (2004) Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy (in submission).
53. Calvo, K. R., et al. (2004) Clinical proteomics: in vivo molecular signaling profiles of human tumors, pre and post tumor perfusion with experimental chemotherapy (in preparation).
54. A. Brazma 2001 Minimum information about a microarray experiment (MIAME)-toward standards for microarray data Nat. Genet 29 4 365 371
55. A. J. Carlisle 2000 Development of a prostate cDNA microarray and statistical gene expression analysis package Mol. Carcinogen 28 1 12 22
56. P. Cutler 2003 Protein arrays: the current state-of-the-art Proteomics 3 1 3 18
57. A. Sreekumar 2001 Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins Cancer Res 61 20 7585 7593
58. J. C. Miller 2003 Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers Proteomics 3 1 56 63
59. P. Blume-Jensen T. Hunter 2001 Oncogenic kinase signalling Nature 411 6835 355 365
60. R. Ishizawar S. J. Parsons 2004 c-Src and cooperating partners in human cancer Cancer Cell 6 3 209 214
61. M. T. Kloth 2003 STAT5b, a mediator of synergism between c-Src and the epidermal growth factor receptor J. Biol. Chem 278 3 1671 1679
62. J. L. Bos 1989 Ras oncogenes in human cancer: a review Cancer Res 49 17 4682 4689
63. A. Sparmann D. Bar-Sagi 2004 Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis Cancer Cell 6 5 447 458
64. A. L. Jones B. Leyland-Jones 2004 Optimizing treatment of HER2-positive metastatic breast cancer Semin. Oncol 31 5 Suppl 10 29 34
65. B. Leyland-Jones 2002 Trastuzumab: hopes and realities Lancet Oncol 3 3 137 144
66. J. S. Sebolt-Leopold 2004 MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors Curr. Pharm. Des 10 16 1907 1914
67. P. Traxler 2003 Tyrosine kinases as targets in cancer therapy-successes and failures Expert Opin. Ther. Targets 7 2 215 234
68. B. J. Druker 2004 Imatinib as a paradigm of targeted therapies Adv. Cancer Res 91 1 30
69. V. Espina 2004 Use of proteomic analysis to monitor responses to biological therapies Expert Opin. Biol. Ther 4 1 83 93
70. E. Petricoin 2004 Clinical proteomics: revolutionizing disease detection and patient tailoring therapy J. Proteome Res 3 2 209 217
71. J. M. Irish 2004 Single cell profiling of potentiated phospho-protein networks in cancer cells Cell 118 2 217 228
72. N. Normanno 2002 Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth Ann. Oncol 13 1 65 72
73. Tibes, R., Trent J., and Kurzrock R. (2004) Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Annu. Rev. Pharmacol. Toxicol.
74. M. Crul 2001 Ras biochemistry and farnesyl transferase inhibitors: a literature survey Anticancer Drugs 12 3 163 184
75. P. Traxler 2001 Tyrosine kinase inhibitors: from rational design to clinical trials Med. Res. Rev 21 6 499 512
76. E. Zwick J. Bange A. Ullrich 2002 Receptor tyrosine kinases as targets for anticancer drugs Trends Mol. Med 8 1 17 23